![Els NIEUWENHUYSEN | Universitair Ziekenhuis Leuven, Leuven | UZ Leuven | Department of Gynaecology and obstetrics | Research profile Els NIEUWENHUYSEN | Universitair Ziekenhuis Leuven, Leuven | UZ Leuven | Department of Gynaecology and obstetrics | Research profile](https://www.researchgate.net/publication/353962339/figure/fig1/AS:1058034809839616@1629266564143/figure-fig1_Q320.jpg)
Els NIEUWENHUYSEN | Universitair Ziekenhuis Leuven, Leuven | UZ Leuven | Department of Gynaecology and obstetrics | Research profile
![IJMS | Free Full-Text | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology IJMS | Free Full-Text | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology](https://pub.mdpi-res.com/ijms/ijms-19-02473/article_deploy/html/images/ijms-19-02473-g001.png?1570391333)
IJMS | Free Full-Text | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
![2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer | International Journal of Gynecologic Cancer 2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/32/Suppl_2/A51.1/F1.large.jpg)
2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer | International Journal of Gynecologic Cancer
![Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer | npj Genomic Medicine Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer | npj Genomic Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41525-022-00300-5/MediaObjects/41525_2022_300_Fig1_HTML.png)